Alpha 2.0
Login Register
» Articles » PMID: 37045523

Time to Benefit With Sotagliflozin in Patients With Worsening Heart Failure

Overview
Journal J Am Coll Cardiol
Specialty Cardiology & Vascular Diseases
Date 2023 Apr 12
PMID 37045523
Authors
Subodh Verma
Deepak L Bhatt
Nitish K Dhingra
Ph Gabriel Steg
Michael Szarek
Michael Davies
Marco Metra
Lars H Lund
Bertram Pitt
Affiliations
Soon will be listed here.
Citing Articles

The contemporary role of sodium-glucose co-transporter 2 inhibitor (SGLT2i) and angiotensin receptor-neprilysin inhibitor (ARNI) in the management of heart failure: State-of-the-art review.

Ezhumalai B, Modi R, Panchanatham M, Kaliyamoorthy D Indian Heart J. 2024; 76(4):229-239.

PMID: 39009078 PMC: 11451353. DOI: 10.1016/j.ihj.2024.07.005.

Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.

Sridhar V, Bhatt D, Odutayo A, Szarek M, Davies M, Banks P Clin J Am Soc Nephrol. 2024; 19(5):557-564.

PMID: 38277468 PMC: 11108248. DOI: 10.2215/CJN.0000000000000414.

Time to Benefit of Sodium-Glucose Cotransporter-2 Inhibitors Among Patients With Heart Failure.

Chen K, Nie Z, Shi R, Yu D, Wang Q, Shao F JAMA Netw Open. 2023; 6(8):e2330754.

PMID: 37615988 PMC: 10450563. DOI: 10.1001/jamanetworkopen.2023.30754.